Chronic Lymphocytic Leukemia Clinical Trial

Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter’s Transformation

Summary

The purpose of this study is to evaluate the safety and effectiveness of targeted immunotherapy in combination with ublituximab and umbralisib, in patients with advanced leukemia-cll/" >CLL or Richter's Transformation.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Confirmed diagnosis of B-cell Chronic Lymphocytic Leukemia or Richter's Transformation
Refractory to or relapsed after at least 1 prior treatment regimen
Eastern Cooperative Oncology Group (ECOG) score of 0 to 2

Exclusion Criteria:

Any major surgery, chemotherapy or immunotherapy within the last 14 days
Known hepatitis B virus, hepatitis C virus or HIV infection
Active autoimmune disorder (with the exception of autoimmune hemolytic anemia or ITP)

Study is for people with:

Chronic Lymphocytic Leukemia

Phase:

Phase 1

Estimated Enrollment:

27

Study ID:

NCT02535286

Recruitment Status:

Completed

Sponsor:

TG Therapeutics, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 4 Locations for this study

See Locations Near You

TG Therapeutics Investigational Trial Site
New York New York, 10065, United States
TG Therapeutics Investigational Trial Site
Durham North Carolina, 27710, United States
TG Therapeutics Investigational Trial Site
Philadelphia Pennsylvania, 19104, United States
TG Therapeutics Investigational Trial Site
Seattle Washington, 98109, United States

How clear is this clinincal trial information?

Study is for people with:

Chronic Lymphocytic Leukemia

Phase:

Phase 1

Estimated Enrollment:

27

Study ID:

NCT02535286

Recruitment Status:

Completed

Sponsor:


TG Therapeutics, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.